Comment
doi: 10.1016/S0140-6736(18)32606-0.
Epub 2018 Oct 22.
A new opportunity after migraine treatment failure?
Affiliations
- PMID: 30360967
- DOI: 10.1016/S0140-6736(18)32606-0
Item in Clipboard
Comment
A new opportunity after migraine treatment failure?
Lancet.
.
No abstract available
Comment on
-
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22. Lancet. 2018. PMID: 30360965 Clinical Trial.
Similar articles
-
Erenumab succeeds in alleviating migraine where other treatments fail.Nat Rev Neurol. 2018 Dec;14(12):691. doi: 10.1038/s41582-018-0104-x. Nat Rev Neurol. 2018. PMID: 30425344 No abstract available.
-
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.Lancet Neurol. 2014 Sep;13(9):885-92. doi: 10.1016/S1474-4422(14)70128-0. Epub 2014 Aug 10. Lancet Neurol. 2014. PMID: 25127173 Clinical Trial.
-
Galcanezumab CONQUERs migraine prevention.Lancet Neurol. 2020 Oct;19(10):798-799. doi: 10.1016/S1474-4422(20)30324-0. Epub 2020 Sep 16. Lancet Neurol. 2020. PMID: 32949530 No abstract available.
-
CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.Curr Pain Headache Rep. 2018 Apr 6;22(5):38. doi: 10.1007/s11916-018-0686-4. Curr Pain Headache Rep. 2018. PMID: 29623520 Review.
-
Erenumab is effective in reducing migraine frequency and improving physical functioning.BMJ Evid Based Med. 2019 Apr;24(2):76. doi: 10.1136/bmjebm-2018-110937. Epub 2018 Aug 14. BMJ Evid Based Med. 2019. PMID: 30108057 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
